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Please cite this article as: B.J. Monk, et al.,
(TRINOVA-1): Long-term survival,..., GynecoPatients andmethods.Womenwith recurrent disease (platinum-free interval b 12months) were randomized
to receive intravenous paclitaxel 80 mg/m2 (3 weeks on/1 week off) plus intravenous trebananib 15 mg/kg or
placebo, weekly. OS in the intent-to-treat population was a key secondary endpoint. Exploratory analysis of
PFS-2 was conducted according to guidance by the European Medicines Agency.
Results. Median OS was not signiﬁcantly improved with trebananib compared with placebo (19.3 versus
18.3 months; HR, 0.95; 95% CI, 0.81–1.11; P = 0.52) in the intent-to-treat population (n = 919). In subgroup
analysis, trebananib improved median OS compared with placebo (14.5 versus 12.3 months; HR, 0.72; 95% CI,
0.55–0.93; P=0.011) in patientswith ascites at baseline (n=295). In the intent-to-treat population, trebananib
signiﬁcantly improved median PFS-2 compared with placebo (12.5 versus 10.9 months; HR, 0.85; 95% CI,
0.74–0.98; P = 0.024). The incidence and type of adverse events in this updated analysis was consistent with
that described in the primary analysis; no new safety signals were detected.
Conclusions. OS was not signiﬁcantly longer in the intent-to-treat population, although there was an improve-
ment in OS in patients with ascites receiving trebananib. PFS-2 conﬁrmed that the PFS beneﬁt associated with
trebananib was maintained through the second disease progression independent of the choice of subsequent
therapy.
© 2016 Elsevier Inc. All rights reserved.Keywords:
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First-line treatment with a platinum/taxane combination therapy is
effective in the treatment of ovarian cancer, but recurrence/relapse is
frequent and outcomes are poor, particularly for those patients with a
platinum-free interval b 12 months [1]. In addition to poor overall sur-
vival (OS), ovarian cancer is often associated with debilitating symp-
toms. More than one third of patients diagnosed with the disease
have malignant ascites, which can result in abdominal pain, dyspnea,
nausea, vomiting, and anorexia [2,3]. Presence of ascites plays a major
role in progression of ovarian cancer and is associated with poor prog-
nosis [2,3].
The tumor microenvironment and, speciﬁcally, tumor angiogenesis,
is involved in ovarian cancer development, progression, and metastasis
[4]. Angiogenesis is controlled by growth factors, including the vascular
endothelial growth factor (VEGF) pathway and angiopoietin-Tie2 re-
ceptor axis. The angiopoietin axis is distinct from the VEGF pathway;
angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) regulate angiogenesis
and vascular remodeling by interacting with the endothelial receptor
tyrosine kinase, Tie2 [5]. Evidence suggests that the Ang2 pathway
plays a role in the pathophysiology of ovarian cancer [6–8] and upregu-
lation of Ang2 is correlated with poor prognosis in women with recur-
rent ovarian cancer [9]. Several antiangiogenic agents that target the
VEGF pathway have been shown to improve progression-free survival
(PFS) in patientswith ovarian cancer; however, a statistically signiﬁcant
improvement in OS has not been demonstrated [10–18].
Trebananib (AMG 386) is a peptide-Fc fusion protein that binds
Ang1 and Ang2, thus preventing their ligand-receptor interaction with
Tie2 [19]. In a randomized, placebo-controlled, double-blind, phase 3
study (TRINOVA-1), women with recurrent ovarian cancer receiving
paclitaxel plus trebananib 15mg/kg once weekly (QW) had signiﬁcant-
ly prolonged PFS (primary endpoint) compared with patients who re-
ceived paclitaxel plus placebo (7.2 versus 5.4 months; hazard ratio
[HR], 0.66; 95% CI, 0.57–0.77; P b 0.0001) [20] without impairment of
quality of life [21].We report themature analysis of OS in this study. Ad-
ditionally, we provide results from a subgroup analysis that evaluated
outcomes in patients with/without ascites and an exploratory analysis
of time to second disease progression (PFS-2).
2. Methods
2.1. Patients
Eligibility criteria for TRINOVA-1 have been reported previously [20].
Brieﬂy,women (≥18 years)were eligible if they hadmeasurable disease
per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
[22]; as a result, patients with only ascites or pleural effusion at baselineFinal results of a phase 3 stu
l Oncol (2016), http://dx.doi.were excluded from the study.Womenwere eligible if they had ≤3 prior
lines of anticancer therapy, Gynecologic Oncology Group (GOG) perfor-
mance status ≤1, and platinum-free interval ≤ 12months. Womenwith
primary platinum-refractory disease (disease progression during the
ﬁrst 6 cycles or within 6 months after the beginning of primary
platinum-based treatment) were excluded. The protocol was approved
by each center's independent ethics committee. Patients providedwrit-
ten informed consent.
2.2. Study design and treatment
This randomized, double-blind, phase 3 study was conducted at
179 centers globally. Patients were randomly assigned in a 1:1 ratio
to receive intravenous paclitaxel 80 mg/m2 once weekly (3 weeks
on/1 week off) plus either intravenous trebananib 15mg/kg or intrave-
nous placebo once weekly. Randomization was stratiﬁed based on
platinum-free interval (≤6 months versus N6 to 12 months), pres-
ence/absence of measurable disease per RECIST, and geographic region
(North America, Western Europe/Australia, rest of world). Study treat-
ment continued until disease progression, unacceptable toxicity, with-
drawal of consent, or death. Dose modiﬁcations for paclitaxel were
based on attributed toxic effects and allowed for a reduction in dose
of 15 mg/m2 per level. Dose reductions for trebananib and placebo
were not permitted.
2.3. Assessments
Disease was assessed with computed tomography/magnetic reso-
nance imaging of at least the chest, abdomen, and pelvis before cycle
1 and every 8 ± 1 weeks for up to 2 years from time of randomization
and then every 6 ± 1 months thereafter until disease progression.
Imaging was evaluated by the investigator per RECIST version 1.1. The
presence or absence of ascites at baseline (i.e., within 28 days before
randomization) was determined by the investigator at study randomi-
zation and recorded using the electronic case report form. Adverse
events (AEs) occurring from start of treatment until the safety follow-
up visit (30–37 days after last dose) were recorded and graded using
the Common Terminology Criteria for Adverse Events, version 3.0 [23].
Health-related quality of life (HRQoL) was evaluated using Functional
Assessment of Cancer Therapy–Ovary (FACT-O) and EQ-5D instruments
[24,25].
2.4. Statistical analyses
As previously described [20], the planned population size of 900 pa-
tients (followed up until at least 510 patients had disease progression or
died) was estimated to provide 90% statistical power to detect a 33%dy of trebananib plus weekly paclitaxel in recurrent ovarian cancer
org/10.1016/j.ygyno.2016.07.112
Table 1
Baseline demographics and clinical characteristics.
Paclitaxel + Placebo
n = 458
Paclitaxel + Trebananib
15 mg/kg QW
n = 461
Median (range) age, years 59 (22–84) 60 (29–84)
Race/ethnicity, n (%)
White 363 (79) 387 (84)
Asian 82 (18) 58 (13)
Other, including black ethnicity 13 (3) 16 (3)
Region, n (%)
North America 91 (20) 93 (20)
Western Europe/Australia 189 (41) 193 (42)
Rest of world 178 (39) 175 (38)
GOG performance status, n (%)
0 252 (55) 259 (56)
1 205 (45) 200 (43)
2a 1 (b1) 2 (b1)
Primary tumor type, n (%)
Ovarian cancer 419 (91) 423 (92)
Primary peritoneal carcinoma 24 (5) 24 (5)
Fallopian tube cancer 15 (3) 14 (3)
Histologic type, n (%)
Serous 388 (85) 385 (84)
Endometrioid 26 (6) 29 (6)
Otherb 44 (10) 47 (10)
Histologic grade, n (%)
Well differentiated 31 (7) 24 (5)
Moderately differentiated 84 (18) 69 (15)
Poorly differentiated 256 (56) 274 (59)
Unknown 87 (19) 94 (20)
Prior lines of therapy, n (%)
1 172 (38) 190 (41)
2 172 (38) 174 (38)
3 114 (25) 95 (21)
4a 0 (0) 2 (b1)
Platinum-free interval, n (%)c
≤ 6 months 245 (53) 235 (51)
N 6 to ≤12 months 212 (46) 223 (48)
Measurable disease at baseline,
n (%)
433 (95) 436 (95)
Baseline ascites, n (%) 141 (31) 154 (34)
GOG, Gynecologic Oncology Group; QW, once weekly.
a Protocol deviation.
b Includes undifferentiated and transitional. Clear cell and mucinous histologies were
excluded by protocol.
c Four patients were refractory (protocol deviation).
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error to 5%. A prespeciﬁed interim analysis of OS was performed at the
time of primary analysis of PFS [20]. Primary analysis of OS was condi-
tional on a demonstration of statistically signiﬁcant improvement in
PFS and was planned for when a minimum of 600 deaths had occurred.
With 600 events, the study was estimated to have 85% statistical power
to detect a 28% improvement in OS while limiting the overall two-sided
type I error to 5%. Differences between arms in PFS and OS were evalu-
ated using a log-rank test, stratiﬁed by randomization factors. HRs with
95% CIs for PFS and OS were calculated using stratiﬁed Cox regression
models. Baseline characteristics of interest were prespeciﬁed in the
study's statistical analysis plan. After the study was initiated, the
European Medicines Agency (EMA) provided guidance on the use of
PFS-2 as a conﬁrmatory measure of the durability of treatment effect,
whichmay be of particular value whenmultiple lines of therapy are an-
ticipated to limit ability to identify an effect on OS. We evaluated PFS-2
in an exploratory, post hoc analysis, deﬁning it as time from randomiza-
tion to second disease progression, start of second subsequent therapy,
or death from any cause. Analysis of time to second subsequent therapy
(time from randomization to administration of second subsequent ther-
apy) was performed to provide a conﬁrmatory evaluation of the PFS-2
outcomes. All efﬁcacy analyses (PFS, OS, PFS-2, time to ﬁrst/second sub-
sequent therapy) were performed using the intent-to-treat population.
Safety analyses included all randomized patients who received ≥1 dose
of paclitaxel or trebananib/placebo.
3. Results
3.1. Patient demographics and clinical characteristics
Between November 10, 2010, and November 19, 2012, 919 women
were randomized at 179 sites in 32 countries (Supplemental Fig. 1).
The data cutoff date for primary OS analysis was August 29, 2014. Base-
line characteristicswere balanced across both treatment arms (Table 1).
Most patients (61%) had received ≥2 treatment regimens; 52% of all pa-
tients had a platinum-free interval of ≥0 to ≤6 months. Median (range)
follow-up time for trebananib and placebo treatment arms was 18.0
(0–43) months and 17.5 (0–44) months, respectively.
Median (range) number of cycles administered was 6.0 (1–37) in
the trebananib arm and 5.0 (1–43) in the placebo arm. Median relative
dose intensity for paclitaxel was 93% and 92% in the trebananib and
placebo treatment arms, respectively. Themedian relative dose intensi-
ty for trebananib was 97%. Patients in both arms received extensive
anticancer therapy after ceasing study treatment. Overall, 331 patients
(72%) in the trebananib arm and 353 patients (77%) in the placebo
arm received ≥1 subsequent anticancer therapy after disease progres-
sion; 201 patients (44%) in the trebananib arm and 231 (50%) in the pla-
cebo arm received ≥2 subsequent anticancer therapies. Treatments
administered included platinum agents (trebananib arm, n = 198
[60%]; placebo arm, n = 205 [58%]), other cytotoxic agents (trebananib
arm, n = 313 [95%]; placebo arm, n = 331 [94%]), and other
antiangiogenic therapy (trebananib arm, n = 51 [15%]; placebo arm,
n=48 [14%]; Supplemental Table 1). Median (range) number of subse-
quent anticancer therapies administered was 2 (1–8) in both arms.
3.2. Overall survival and mature progression-free survival
In the primary analysis of the intent-to-treat population, paclitaxel
plus trebananib did not signiﬁcantly improve OS compared with
paclitaxel plus placebo. At the time of analysis, 315 patients (68%) in
the trebananib arm and 313 patients (68%) in the placebo arm had
died. Median OS was 19.3 (95% CI, 17.6–21.4) months for paclitaxel
plus trebananib and 18.3 (95% CI, 16.3–20.4) months for paclitaxel
plus placebo (HR, 0.95; 95% CI, 0.81–1.11; P=0.52; Fig. 1A). Evaluation
of OS outcomes in subgroups showed the most notable effect among
patients with ascites at baseline (Fig. 1B). An updated analysis of PFSPlease cite this article as: B.J. Monk, et al., Final results of a phase 3 stu
(TRINOVA-1): Long-term survival,..., Gynecol Oncol (2016), http://dx.doi.operformed at the time of the primary analysis of OS conﬁrmed the pre-
viously reported [20] signiﬁcant prolongation of PFS in the trebananib
arm: median PFS in the trebananib arm was 7.4 (95% CI, 7.0–7.8)
months versus 5.4 (95% CI, 4.7–5.5) months in the placebo arm (HR,
0.70; 95% CI, 0.61–0.80; P b 0.001). In a sensitivity analysis, median
time to ﬁrst subsequent treatment or death (a proxy for PFS) was
7.5 months for the trebananib arm versus 6.0 months for the placebo
arm (HR, 0.82; 95% CI, 0.71–0.94; P= 0.004). For PFS, HRs favored the
trebananib arm for all baseline characteristics evaluated (Fig. 1C).
3.3. Exploratory subgroup analysis of patients with ascites at baseline
At baseline, 295 patients had ascites and 624 patients did not have
ascites. Demographic/clinical characteristics were similar for both pa-
tient groups (Table 2). At the time of this analysis, 107/141 patients
(76%) with ascites in the trebananib treatment arm and 134/154 pa-
tients (87%) with ascites in the placebo arm had died. In this subgroup
analysis, paclitaxel plus trebananib signiﬁcantly prolonged OS in pa-
tients with ascites compared with paclitaxel plus placebo treatment.
Among patients with ascites, median OS in the trebananib arm was
14.5 (95% CI, 11.4–18.6) months versus 12.3 (95% CI, 9.1–13.9) months
in the placebo arm (HR, 0.72; 95%CI, 0.55–0.93; P=0.011; Fig. 2). There
was little evidence that trebananib treatment was associated with ady of trebananib plus weekly paclitaxel in recurrent ovarian cancer
rg/10.1016/j.ygyno.2016.07.112
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Fig. 1. Overall survival in intent-to-treat population (A), overall survival (B), and progression-free survival (C) in subgroups of baseline characteristics. HR, hazard ratio.
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be a trend toward improvement in some instruments (Supplemental
Fig. 2). Among patients without ascites, there was no signiﬁcant differ-
ence in OS between treatment arms. Median OS in the trebananib arm
was 21.4 (95% CI, 19.1–23.6) months compared with 22.8 (95% CI,
20.5–25.9) months in the placebo arm (HR, 1.14; 95% CI, 0.93–1.39;
P= 0.20) (Supplemental Fig. 3).
3.4. Time to second disease progression
To evaluate the durability of the effect of trebananib treatment on
PFS, we performed an exploratory analysis of PFS-2 (i.e., time to second
disease progression; Fig. 3A). At the time of analysis, 405/461 patients
(88%) in the trebananib arm and 413/458 patients (90%) in the placeboPlease cite this article as: B.J. Monk, et al., Final results of a phase 3 stu
(TRINOVA-1): Long-term survival,..., Gynecol Oncol (2016), http://dx.doi.arm had had a PFS-2 event (i.e., a second disease progression after ran-
domization into the study). Median PFS-2 was 12.5 (95% CI, 7.3–18.5)
and 10.9 (95% CI, 10.0–11.5) months for the trebananib and placebo
arms, respectively (HR, 0.85; 95% CI, 0.74–0.98; P= 0.024; Fig. 3B). In
a sensitivity analysis, time to second subsequent treatment was
13.4 months for the trebananib arm versus 11.7 months for the placebo
arm (HR, 0.83; 95% CI, 0.72–0.96; P= 0.011).
3.5. Adverse events
Among patients who received ≥1 dose of study medication, 97% in
the trebananib arm and 96% in the placebo arm had treatment-
emergent AEs of any grade (Table 3). The proportion of patients with
grade ≥ 3 AEs, serious AEs, or fatal AEs was similar in both treatmentdy of trebananib plus weekly paclitaxel in recurrent ovarian cancer
org/10.1016/j.ygyno.2016.07.112
Table 2
Demographics of patients with and without ascites.
Patients with ascites at baseline Patients without ascites at baseline
Paclitaxel
+ Placebo
n = 154
Paclitaxel + Trebananib
15 mg/kg QW
n = 141
All Patients
n = 295
Paclitaxel
+ Placebo
n = 304
Paclitaxel + Trebananib
15 mg/kg QW
n = 320
All Patients
n = 624
Median (range) age, years 58 (32–80) 59 (36–80) 58.0 (32–80) 59 (22–84) 60 (29–84) 60.0 (22–84)
GOG performance status, n (%)
0 73 (47) 61 (43) 134 (45) 179 (59) 198 (62) 377 (60)
1 80 (52) 79 (56) 159 (54) 125 (41) 121 (38) 246 (39)
2a 1 (b1) 1 (b1) 2 (1) 0 1 (b1) 1 (b1)
Primary tumor type, n (%)
Ovarian cancer 140 (91) 125 (89) 265 (90) 279 (92) 298 (93) 577 (93)
Primary peritoneal carcinoma 9 (6) 10 (7) 19 (6) 15 (5) 14 (4) 29 (5)
Fallopian tube cancer 5 (3) 6 (4) 11 (4) 10 (3) 8 (3) 18 (3)
Histologic grade, n (%)
Well differentiated 10 (6) 6 (4) 16 (5) 21 (7) 18 (6) 39 (6)
Moderately differentiated 24 (16) 22 (16) 46 (16) 60 (20) 47 (15) 107 (17)
Poorly differentiated 86 (56) 83 (59) 169 (57) 170 (56) 191 (60) 361 (58)
Unknown 34 (22) 30 (21) 64 (22) 53 (17) 64 (20) 117 (19)
Prior lines of therapy, n (%)
1 62 (40) 60 (43) 122 (41) 110 (36) 130 (41) 240 (39)
2 61 (40) 47 (33) 108 (37) 111 (37) 127 (40) 238 (38)
3 31 (20) 33 (23) 64 (22) 83 (27) 62 (19) 145 (23)
4a 0 1 (b1) 1 (b1) 0 1 (b1) 1 (b1)
Prior antiangiogenic therapy, n (%)
Yes 10 (6) 11 (8) 21 (7) 25 (8) 24 (8) 49 (8)
No 144 (94) 130 (92) 274 (93) 279 (92) 296 (93) 575 (92)
Platinum-free interval, n (%)b
≤ 6 months 94 (61) 78 (55) 172 (58) 151 (50) 157 (49) 308 (49)
N 6 to ≤12 months 60 (39) 63 (45) 123 (42) 152 (50) 160 (50) 312 (50)
Measurable disease at baseline, n (%) 143 (93) 131 (93) 274 (93) 290 (95) 305 (95) 595 (95)
GOG, Gynecologic Oncology Group; QW= once weekly.
a Protocol violation.
b Four patients were refractory (protocol deviation).
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ed with more AE-related treatment discontinuations (22%) than treat-
ment with paclitaxel plus placebo (8%), although this ﬁnding must be
considered in the context of the higher risk of disease progression in
the paclitaxel plus placebo arm.
The proportion of patients who developed edema of any grade
during treatment was greater in the trebananib arm (66%) than in the
placebo arm (30%). The most frequently occurring edema events were
localized edema (59% versus 27%) and generalized edema (12% versus
3%; Table 3). More patients in the trebananib arm (n = 52; 11%) than
in the placebo arm (n = 4; 1%) had grade ≥ 3 edema. There wasFig. 2. Overall survival in patients with ascites at b
Please cite this article as: B.J. Monk, et al., Final results of a phase 3 stu
(TRINOVA-1): Long-term survival,..., Gynecol Oncol (2016), http://dx.doi.oone grade 5 event of generalized edema in the setting of diabetic
ketoacidosis and neutropenic sepsis in the trebananib arm; no other
grade 4/5 edema events occurred during the study. Several other AEs
presented with a higher incidence rate in the trebananib arm. Ascites
of any grade (22% versus 13%) and grade 3 (13% versus 8%) occurred
more frequently with trebananib treatment than with placebo. There
were no grade 4/5 ascites events. Pleural effusion, nasopharyngitis,
and weight increase also occurred more frequently with trebananib
treatment (Table 3). AEs of interest were hypertension (trebananib,
7% versus placebo, 4%), pulmonary embolism (2.2% versus 1.1%), arterial
thrombotic events (0.7% in both arms), venous thromboembolic eventsaseline. HR, hazard ratio; OS, overall survival.
dy of trebananib plus weekly paclitaxel in recurrent ovarian cancer
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Fig. 3. Deﬁnition of PFS-2, based on the Guideline on the Evaluation of Anticancer Medicinal Products inMan, Appendix 1 [30] (A), and exploratory analysis of time to second progression
event (B). HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PFS-2, time to second progression event; TSST, time to second subsequent treatment.
6 B.J. Monk et al. / Gynecologic Oncology xxx (2016) xxx–xxx(7.4% versus 4.4%), gastrointestinal perforation (2.0% versus 0.2%),
impaired wound healing (2.2% versus 1.5%), and blurred vision (6.9%
versus 4.4%).Table 3
Adverse events.
Patients with adverse events, n (%) Paclitaxel
+ Placebo
n = 452
Paclitaxel
+ Trebananib
15 mg/kg QW
n = 461
Any treatment-emergent adverse event 434 (96) 449 (97)
Grade ≥ 3 199 (44) 223 (48)
Grade ≥ 4 36 (8) 29 (6)
Grade 5 20 (4) 26 (6)
Serious adverse event 138 (31) 167 (36)
Adverse event leading to discontinuation
of trebananib
34 (8) 101 (22)
Treatment-emergent adverse events with ≥5%
difference in incidence between arms
Localized edema 122 (27) 272 (59)
Pleural effusion 18 (4) 67 (15)
Ascites 57 (13) 101 (22)
Generalized edema 12 (3) 54 (12)
Weight increased 10 (2) 44 (10)
Nasopharyngitis 31 (7) 59 (13)
Neutropenia 129 (29) 104 (23)
Anemia 94 (21) 50 (11)
QW, once weekly.
Please cite this article as: B.J. Monk, et al., Final results of a phase 3 stu
(TRINOVA-1): Long-term survival,..., Gynecol Oncol (2016), http://dx.doi.4. Discussion
In the TRINOVA-1 study, the combination of paclitaxel plus trebananib
15 mg/kg QW signiﬁcantly prolonged PFS (the study's primary endpoint)
compared with paclitaxel plus placebo in women with recurrent ovarian
cancer, with beneﬁt across most patient subgroups evaluated [20]. Al-
though treatment with paclitaxel plus trebananib did not signiﬁcantly
prolongmedianOS in the intent-to-treat population (HR, 0.95; 18.3 versus
19.3 months; P= 0.52), there was a signiﬁcant improvement in median
OS favoring the trebananib arm among patients with ascites at baseline
(HR, 0.72; 14.5 versus 12.3 months; P= 0.011). There was a signiﬁcant
improvement in median PFS in this analysis that was consistent with
that of the primary analysis of PFS [20]. Similarly, the incidence and nature
of AEs was consistent with that described in the primary analysis of PFS;
there were no new safety signals [20].
Overall survival has historically been regarded as among the most
objective and clinically relevant endpoints in cancer studies. However,
it has proven exceptionally difﬁcult to show a statistically signiﬁcant
prolongation of OS with the addition of targeted therapy to standard
treatments in patients with ovarian cancer [10–18,26–28]. Potential
confounding factors for OS include the long postprogression survival
period, the administration of multiple postprogression therapies, and
the potential for postprogression crossover [27,29]. In the TRINOVA-1
study, 47% of patients had received at least two lines of postprogression
therapy, and 14% received an antiangiogenic therapy after progression.dy of trebananib plus weekly paclitaxel in recurrent ovarian cancer
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to assess the durability of treatment effect by evaluating postprogression
endpoints such as PFS-2 and time to second subsequent therapy (TSST)
[27,30]. The TRINOVA-1 study is among the ﬁrst to demonstrate that an
antiangiogenic therapy signiﬁcantly delayed the time to second progres-
sion (i.e. PFS-2) in women with recurrent ovarian cancer. Consistent
with the exploratory analysis of PFS-2, a conﬁrmatory analysis that eval-
uated TSST also showed beneﬁt in the trebananib arm. These results indi-
cate that the PFS beneﬁt achieved with trebananib was maintained
through at least the second disease progression following enrollment in
the study irrespective of the second therapy administered. Patients re-
ceived multiple lines of postprogression therapy (up to 8 lines, including
both chemotherapy and targeted agents), which are likely to have con-
founded the analysis of OS. The data suggest that, although a signiﬁcant
improvement in OS was not achieved in the intent-to-treat population,
trebananib provided a clinically meaningful beneﬁt and that this beneﬁt
was maintained at least through the second disease progression, without
impairment of quality of life [21].
A second approach to the challenges of demonstrating an OS beneﬁt
in recurrent ovarian cancer is to evaluate outcomes in patient subgroups
likely to derive particular beneﬁt from treatment. In a subgroup analy-
sis, we found that median OS was signiﬁcantly longer in patients with
ascites at baseline who received paclitaxel plus trebananib compared
with patients who received paclitaxel plus placebo. Although PFS was
improved among patients without ascites at baseline, this beneﬁt was
not maintained postprogression. As has been observed in other studies
in patients with ovarian cancer [31,32], there was no signiﬁcant differ-
ence in OS between treatment arms in patients without ascites. The
presence of malignant ascites in advanced ovarian cancer has been
associated with disease recurrence and poor prognosis [33,34], and we
found that median OS was much shorter in patients with ascites
(trebananib, 14.5 months; placebo, 12.3 months) than those without
(trebananib, 22.8 months; placebo, 21.4 months) irrespective of treat-
ment arm [33,34].
Evidence indicates that angiogenic pathways play an important role
in the formation of ascites in ovarian cancer [9,33]. The presence of
ascites at baseline has been shown to be associated with poor prognosis
and is considered a sign of peritoneal carcinomatosis [3]. Peritoneal
carcinomatosis has been shown to be particularly dependent on angio-
genesis and as a result, may be susceptible to antiangiogenic therapy
[33]. In this context, it is notable that improvements in outcomes have
also been observed in studies with other antiangiogenic agents in
ovarian cancer patients with ascites. Speciﬁcally, subgroup analyses
showed improved OS in patients with ovarian cancer who received
bevacizumab in the AURELIA (recurrent disease) [17], GOG 218 (ﬁrst-
line) [32], and ICON7 (ﬁrst-line) [18] phase 3 clinical studies. Amongpa-
tients with ascites at baseline in the AURELIA study (n = 113), there
was a trend toward longer median OS among patients who received
bevacizumab plus chemotherapy comparedwith patients who received
placebo plus chemotherapy in the subgroup of patients with ascites at
baseline (11.7 versus 7.9 months; HR, 0.67; 95% CI, 0.45–1.00) [31]. Al-
though angiogenic factors may play a role in ascites formation [35,36],
there are other factors thatmay also lead to formationof ascites in ovarian
cancer. Although a subgroup analysis, it must be noted that TRINOVA-1
was of sufﬁcient size overall that the ascites subgroup analysis contained
295 patients in which an OS beneﬁt was shown. Results from this study
suggest that use of ascites as a stratiﬁcation factor in future trials of
antiangiogenic agents in ovarian cancer may be appropriate.
The AEs reported at the time of the mature OS analysis were consis-
tent with those previously reported in the primary analysis [20], as
would be anticipated given the limited additional exposure. The most
common AE associated with trebananib treatment was low-grade
edema, which was also described in both the TRINOVA-1 primary
analysis [20] and in other trebananib studies [37]. Incidences of AEs
common to anti-VEGF therapies, such as hypertension, hemorrhage,
proteinuria, thrombotic events, and pulmonary embolisms, were notPlease cite this article as: B.J. Monk, et al., Final results of a phase 3 stu
(TRINOVA-1): Long-term survival,..., Gynecol Oncol (2016), http://dx.doi.osigniﬁcantly increased in the trebananib treatment group compared
with placebo, which is consistent with the toxicity proﬁle of trebananib
reported in previous studies [37].
In summary, paclitaxel plus weekly trebananib did not signiﬁcantly
prolong OS in the intent-to-treat population compared with paclitaxel
plus placebo. As in the previously reported primary analysis, PFS
remained signiﬁcantly longer with trebananib treatment. In an explor-
atory subgroup analysis, we showed that both PFS and OS were
improved with trebananib in the clinically important subgroup of
patients with ascites at baseline. This suggests that trebananib, as
other antiangiogenic drugs, may have particular value in the group of
poor prognosis patients who have ascites. Additionally, consistent
with guidance from the EMA,we evaluated PFS-2 as an exploratory end-
point and demonstrated that the PFS beneﬁt associatedwith trebananib
was durable and was maintained through at least the second disease
progression independent of the choice of subsequent therapy.
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